Navigation Links
Sangui BioTech Files Three 2007 Quarterly Reports, Sales Increased, Losses Continue
Date:6/20/2008

WITTEN, Germany, June 20 /PRNewswire-FirstCall/ -- Sangui BioTech International, Inc., has now filed its quarterly reports on Form 10QSB with the SEC covering the quarters ended September 30, 2006; December 31, 2006, and March 31, 2007. In the first nine month of its 2007 financial year the company generated sales of approximately USD 345,000 as compared to approximately USD 95,000 in the first nine months of FY 2006. Operating expenses amounted to almost USD 600,000. The increase as compared to the USD 356,000 in the previous year period is due to increased efforts to expand operations to international markets. The company incurred a net loss of approximately USD 486,000. Sangui used cash in operating acitivities of approximately USD 457,000 (2006 period: approximately USD 242,000). The company's accumulated deficit amounted to USD 22.3 million as of March 31, 2007.

Apart from the contribution margin generated from sales of its cosmetics and wound management products, operations in the first nine months of FY 2007 were financed by investments from several European investors in the amount of approximately USD 543,000. In accordance with US-GAAP the amount is shown as Foreign currency translation adjustments in the profit-and-loss statement and as Effect of exchange rate changes in the cash-flow statement respectively.

In the first nine months of its financial year 2008 (July 1, 2007 through March 31, 2008), Sangui BioTech International, Inc., generated hardly any sales. The company invested in identifying and establishing new sales opportunities in international markets, to wit Mexico and the Arab countries, as well as in the approval process of its Hemospray wound spray in accordance with European, Mexican and US regulations. Ensuing losses were financed by continued investments from several European investors.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49(160)741-27-17

Fax: +49(2302)915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui BioTech International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Biotech Finishes on a High in August, Burrill Report Says
3. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
4. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
5. Biotech delists shares from TSXV, continues OTCBB trading
6. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
7. MichBio Announces Formation of Biotechnology Legislative Caucus
8. Oncolytics Biotech Inc. announces approval for UK clinical trial
9. Not just humans benefit from animal biotechnology
10. Biotech adds Central American markets to Sucanon distribution
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell ... years. The technology is so cutting edge, in fact, the U.S. Food and ... cell procedures. However, successful patient outcomes in certain clinical stem cell procedures have ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... South Bend’s ... proud to once again feature Heroes On The Water (HOW), a non-profit organization dedicated ... all new episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, ...
(Date:2/22/2017)... ... 22, 2017 , ... A cylindrical “pipeline” used for treating ... reach ones, according to the results of a clinical trial announced Wednesday. , ... Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and Lyerly Neurosurgery ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Using the ... leads utilizing a simple online checklist. Over a period of just 24 months, thousands ... assistance of an online checklist called T.A.D. , “The internet is not getting quieter. ...
(Date:2/22/2017)... ... 22, 2017 , ... Becker’s Spine Review, the leading publication ... neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” http://www.beckersspine.com/spine-leaders/item/35348- . ... Michigan performing minimally invasive back surgery that often results in less post-operative discomfort ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Mixed tocopherols market projected to grow at ... is projected to reach USD 5.27 billion by 2022, at ... by factors such as health and wellness trends, for instance, ... regulations for sourcing, processing, packaging, and labeling of food & ... such as the Asia-Pacific region also ...
(Date:2/22/2017)... 2017 a condition where an organ ... due to weak abdominal wall. Hernia is classified ... hernia, femoral hernia, umbilical hernia, and other (hiatal ... surgeries are performed using a mesh, made-up of ... devices. Among the available options, open tension-free repair ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds leading ... Description The Global Spinal Cord Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology: